Cross-sectional health centre and community-based evaluation of the impact of pneumococcal and malaria vaccination on antibiotic prescription and usage, febrile illness and antimicrobial resistance in young children in Malawi: the IVAR study protocol

Author:

Singleton DavidORCID,Ibarz-Pavon Ana,Swarthout Todd DORCID,Bonomali Farouck,Cornick Jennifer,Kalizang’oma Akuzike,Ntiza Noah,Brown Comfort,Chipatala Raphael,Nyangulu Wongani,Chirombo James,Kawalazira Gift,Chibowa Henry,Mwansambo Charles,Maleta Kenneth Mphatso,French Neil,Heyderman Robert SORCID

Abstract

IntroductionVaccination is a potentially critical component of efforts to arrest development and dissemination of antimicrobial resistance (AMR), though little is known about vaccination impact within low-income and middle-income countries. This study will evaluate the impact of vaccination on reducing carriage prevalence of resistantStreptococcus pneumoniaeand extended spectrum beta-lactamase-producingEscherichia coliandKlebsiellaspecies. We will leverage two large ongoing cluster-randomised vaccine evaluations in Malawi assessing; first, adding a booster dose to the 13-valent pneumococcal conjugate vaccine (PCV13) schedule, and second, introduction of the RTS,S/AS01 malaria vaccine.Methods and analysisSix cross-sectional surveys will be implemented within primary healthcare centres (n=3000 users of outpatient facilities per survey) and their local communities (n=700 healthy children per survey): three surveys in Blantyre district (PCV13 component) and three surveys in Mangochi district (RTS,S/AS01 component). We will evaluate antibiotic prescription practices and AMR carriage in children ≤3 years. For the PCV13 component, surveys will be conducted 9, 18 and 33 months following a 3+0 to 2+1 schedule change. For the RTS,S/AS01 component, surveys will be conducted 32, 44 and 56 months post-RTS,S/AS01 introduction. Six health centres in each study component will be randomly selected for study inclusion. Between intervention arms, the primary outcome will be the difference in penicillin non-susceptibility prevalence amongS. pneumoniaenasopharyngeal carriage isolates in healthy children. The study is powered to detect an absolute change of 13 percentage points (ie, 35% vs 22% penicillin non-susceptibility).Ethics and disseminationThis study has been approved by the Kamuzu University of Health Sciences (Ref: P01-21-3249), University College London (Ref: 18331/002) and University of Liverpool (Ref: 9908) Research Ethics Committees. Parental/caregiver verbal or written informed consent will be obtained prior to inclusion or recruitment in the health centre-based and community-based activities, respectively. Results will be disseminated via the Malawi Ministry of Health, WHO, peer-reviewed publications and conference presentations.

Funder

UK Department of Health

NIHR

Wellcome Trust

National Institute of Health

Publisher

BMJ

Subject

General Medicine

Reference46 articles.

1. WHO . 10 global health issues to track in 2021. Available: https://www.who.int/news-room/spotlight/10-global-health-issues-to-track-in-2021 [Accessed 28 Feb 2022].

2. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis

3. Global antimicrobial resistance: from surveillance to stewardship. Part 1: surveillance and risk factors for resistance

4. Evidence for action: a one health learning platform on interventions to tackle antimicrobial resistance;Wernli;Lancet Infect Dis,2020

5. O’Neill J . Tackling drug-resistant infections globally: final report and recommendations. 2016. Available: http://amr-review.org/home

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3